---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-088051"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:01:34.769560+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics Q2 net loss $20.4M; DKN-01 ORR 33% in CRC; $40M PIPE completed

## Summary
- Net loss of $20.4M in Q2 2024 vs $13.4M in Q2 2023; R&D expenses rose to $17.9M on trial costs.
- DKN-01 combo achieved 33% ORR (38% left-sided) in Part A of DeFianCe CRC study; median PFS 6.3 months.
- Enrollment in Part B expanded to 180 patients; completion expected Sept 2024, data mid-2025.
- DisTinGuish Part C gastric/GEJ cancer data expected Q4 2024 or early 2025.
- Completed $40M private placement with Gilead, Samsara, others; cash $78.5M funds into Q2 2026.

## SEC filing metadata
- accession: 0001104659-24-088051
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465924088051/0001104659-24-088051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465924088051/tm2421304d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-088051
- JSON: https://secwatch.observer/filing/0001104659-24-088051.json
- Plain text: https://secwatch.observer/filing/0001104659-24-088051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.